A Phase II Trial of AZD0530 in Hormone Refractory Prostate Cancer (HRPC).

Trial Profile

A Phase II Trial of AZD0530 in Hormone Refractory Prostate Cancer (HRPC).

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Oct 2016

At a glance

  • Drugs Saracatinib (Primary)
  • Indications Prostate cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 13 Nov 2008 Status changed from active, no longer recruiting to completed, as reported in ClinicalTrials.gov record.
    • 25 Mar 2008 Status changed from recruiting to in progress, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top